Trial Profile
Feasibility and Prospective Randomized Study of Transarterial Chemoembolization using Irinotecan Bead in Combination with Second Line Chemotherapy in the Treatment of Patients with Unresectable Metastatic Colorectal Cancer (PARAGON)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Irinotecan
- Indications Colorectal cancer; Liver metastases
- Focus Therapeutic Use
- Acronyms PARAGON-I
- 26 Aug 2010 The trial has received FDA approval for continuing into a randomised phase IIb trial, with results expected in 2012, as reported in a Biocompatibles International media release.
- 03 Jul 2010 Promising results have been presented at the World Congress for Gastro-Intestinal Cancer, as reported in a Biocampatibles International media release.
- 16 Dec 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.